NCT01975142 In a prospective phase II clinical trial, researchers evaluated the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic efficacy in patients with breast cancer (MBC) whose circulating tumor cells (CTCs) were HER2-positive. Here, ERBB2 is linked to neoplasm.